Published in N Engl J Med on June 12, 1997
What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (1999) 13.99
Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. CMAJ (1998) 1.59
Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS (2011) 1.15
Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. AIDS (2010) 1.11
Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis (2008) 1.10
An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol (2008) 0.97
Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child (2001) 0.90
Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. J Acquir Immune Defic Syndr (2013) 0.87
Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity. J Acquir Immune Defic Syndr (2016) 0.82
Vitamin D-related host genetic variants alter HIV disease progression in children. Pediatr Infect Dis J (2013) 0.81
HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children. J Acquir Immune Defic Syndr (2011) 0.80
The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc (2015) 0.79
Pharmacotherapy of pediatric and adolescent HIV infection. Ther Clin Risk Manag (2009) 0.78
Associations of host genetic variants on CD4⁺ lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J (2014) 0.77
Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS One (2016) 0.75
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 0.75
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science (1997) 8.90
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med (1989) 7.52
Transmission of group B streptococci among parturient women and their neonates. J Pediatr (1973) 6.86
Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr (1973) 6.29
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med (1976) 5.78
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet (1999) 4.61
Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol (1977) 4.46
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Selective broth medium for isolation of group B streptococci. Appl Microbiol (1973) 4.42
Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis (1974) 4.41
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med (1999) 4.12
Group B streptococcal infections in infants. The importance of the various serotypes. JAMA (1974) 3.71
Typing of group B streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J Clin Microbiol (1993) 3.52
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Iron and the sex difference in heart disease risk. Lancet (1981) 3.45
Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol (1982) 3.23
Nontypable Haemophilus influenzae (biotype 4) as a neonatal, maternal, and genital pathogen. Rev Infect Dis (1983) 3.23
Active oxygen in plant pathogenesis. Annu Rev Phytopathol (1995) 3.02
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis (2001) 2.95
HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet (1992) 2.93
Molecular cloning of a Pseudomonas syringae pv. syringae gene cluster that enables Pseudomonas fluorescens to elicit the hypersensitive response in tobacco plants. J Bacteriol (1988) 2.84
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus. J Exp Med (1976) 2.55
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS (2000) 2.49
Involvement of plasma membrane calcium influx in bacterial induction of the k/h and hypersensitive responses in tobacco. Plant Physiol (1990) 2.46
Neonatal sepsis caused by a new group B streptococcal serotype. J Pediatr (1993) 2.45
Microcapsule of type III strains of group B Streptococcus: production and morphology. Infect Immun (1976) 2.38
Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol (1992) 2.37
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med (1992) 2.33
Immune response after splenectomy. Lancet (1978) 2.31
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31
Pituitary function after treatment of intracranial tumours in children. Lancet (1975) 2.25
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods. J Infect Dis (2000) 2.25
Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest (1977) 2.23
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS (1999) 2.23
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci. Infect Immun (1978) 2.15
Comparison of bacteriological methods for the isolation of group of B Streptococcus from vaginal cultures. J Clin Microbiol (1976) 2.14
Changing epidemiology of group B streptococcal colonization. Pediatrics (1999) 2.09
Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med (1996) 2.08
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Implementing family-focused HIV care and treatment: the first 2 years' experience of the mother-to-child transmission-plus program in Abidjan, Côte d'Ivoire. Trop Med Int Health (2009) 2.07
Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med (1979) 2.06
Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis (1987) 2.06
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest (1996) 2.05
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
The 1997 AAP guidelines for prevention of early-onset group B streptococcal disease. American Academy of Pediatrics. Pediatrics (1997) 2.04
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol (2000) 2.04
Tenascin: cDNA cloning and induction by TGF-beta. EMBO J (1988) 2.01
Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA (1998) 2.00
Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A (1980) 2.00
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob Agents Chemother (1998) 2.00
Evaluation of a home-based intervention program to reduce infant passive smoking and lower respiratory illness. J Behav Med (1994) 1.97
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest (1978) 1.95
Improvements in survival from childhood cancer: results of a population based survey over 30 years. Br Med J (Clin Res Ed) (1988) 1.94
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. J Clin Microbiol (1989) 1.87
Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med (1975) 1.86
Endocrine function following the treatment of acute leukemia in childhood. J Pediatr (1977) 1.86
Influenza virus infection in nude mice. J Infect Dis (1976) 1.85
Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics (1981) 1.83
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med (2007) 1.83
Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80
Use of tumour marker immunoreactivity to identify primary site of metastatic cancer. BMJ (1993) 1.79
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis (2000) 1.79
Persistent bacteremia due to coagulase-negative staphylococci in low birth weight neonates. Pediatrics (1989) 1.78
Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol (1989) 1.77
Vaginal colonization with group B streptococcus: a study in college women. J Infect Dis (1977) 1.76
Group B streptococcal vaccines. Rev Infect Dis (1985) 1.74
Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. J Clin Oncol (1995) 1.74
Group B streptococcal infections. Adv Intern Med (1980) 1.72
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Antimicrobial susceptibility of group B streptococci isolated from a variety of clinical sources. Antimicrob Agents Chemother (1976) 1.72
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 1.72
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol (1998) 1.71
Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis (1979) 1.71
Group B streptococcal cellulitis-adenitis in infants. Am J Dis Child (1982) 1.71
Single oral dose metronidazole therapy for Gardnerella vaginalis vaginitis in adolescent females. J Adolesc Health Care (1983) 1.70
Cytological grading of breast carcinoma--a feasible proposition? Cytopathology (1990) 1.70
HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol (1995) 1.69
Human immunodeficiency virus transmission by child sexual abuse. Am J Dis Child (1991) 1.69
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med (1999) 1.69
Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A (1995) 1.68
Phenotypic diversity in the alpha C protein of group B streptococci. Infect Immun (1991) 1.64